Genomic diagnostic tests can accurately identify targeted treatments for cancer patients.
The tests lay the foundation for precision medicine, also called personalised or targeted medicine.
As a bonus: pharmacogenomic tests can determine whether the patient can metabolise (digest/absorb) the identified target treatment successfully.
These two tests have revolutionised cancer medicine with targeted treatments achieving better outcomes and minimal side effects.
Cancer patients now have a choice between the old and new cancer technologies.
Despite recent advances, the old 'one size fits all' model is still common in both conventional, complementary and alternative cancer medicines.
One size fits all approaches are commonplace in...
- Our hospitals - this is the Gold Standard of Cancer Care. Hospitals are limited by finances and hospital/insurance company protocols)
- Supplements, super-foods or extreme diet approaches - the outdated assumption that certain diet regimes are good for all cancer patients.
- Any generic advice from Dr Google, family, friends, workmates is by nature, one size fits all, and may do more harm than good, can cause cancer.
From Genome Mag - “Most often today, your treatment plan isn’t about you specifically.
It’s what doctors would give to anyone with the same condition — your neighbour, the hot dog vendor, or the prime minister of Bangladesh.
Most cancer medicine revolves around “standards of care,” that is providing the best courses of prevention or treatment for the average person on the street.
With breast cancer, for example, those standards mean self-exams and mammograms after a set age and the usual chemotherapy, surgery to treat a tumour if one is found.
If the first treatment doesn’t work, doctors and patients move on to the next one and the next. It’s trial and error, with life on the line.
But each cancer in each person has its own genetic makeup - each tumour is a unique character with unique tendencies and vulnerabilities.
In some cases, the current standard of care may be the safest, most sensible option, but it’s also one size fits all.
Sometimes that’s sufficient, but not always."
Testimonial to the new cancer technologies.
The patient, Jeffrey Deslandes, seen with cancer navigator Grace Gawler, (below) is a 12 year survivor of stage IV non-Hodgkin's lymphoma.
Jeffrey is cancer free because he researched and embraced cancer vaccines delivered by a doctor in Brisbane. Impressed by his results, we referred patients to this doctor until he lost his research funding.
It worked out well: We now help our patients access advanced cancer vaccines via our oncology colleagues in Japan – the outcomes have been exceptional.
The cancer vaccines (immune therapies) are even more effective when used in conjunction with other high-tech treatments.
These include hyperthermia, low-dose radiation, Gamma knife, cyber knife, proton Beam therapy and even surgery.
It is important to understand the difference in these immune therapies to those being used throughout the world.
The blood and tumour blood based immune therapies are very different to the drug based immune therapies made by big pharmaceutical companies.
Drug based immune therapies, while achieving some exceptional outcomes for some cancers, have unpredictable and severe side effects – often much worse than chemotherapy.
On the other hand, blood based immune therapies are predictable, have been used with over 10,000 patients and have minimal or no side effects
A bad deal for Australian Patients
The graph demonstrates that Australia fares poorly when it comes to accessing new medicines. Luckily for patients who find us, our Cancer Navigation Service helps patients access and manage genomic diagnostic tests, pharmacogenomic tests and referrals to new High-Tech Cancer Treatments.